Molsidain (Molsidomine)

Molsidomine, the active ingredient in Molsidain, is a nitric oxide donor presented as an oral tablet formulation for oral administration. It works by releasing nitric oxide, leading to vasodilation and a reduction in myocardial oxygen consumption, and is used in the management of stable angina pectoris in adult patients.

GNH USA supplies Molsidain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Molsidomine acts on the nitric oxide pathway to relieve myocardial ischemia.

Stable angina pectoris: improves exercise tolerance by decreasing myocardial oxygen demand. Chronic stable angina: reduces frequency of anginal attacks during daily activities. Effort‑induced angina: alleviates chest pain triggered by physical exertion.

Molsidomine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Dizziness or light‑headedness: especially on standing. - Flushing: warm sensation with reddening of skin. - Nausea: occasional gastrointestinal upset. - Hypotension: mild blood‑pressure reduction. - Tachycardia: increased heart rate in some patients.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Syncope: fainting episodes linked to hypotension. - Allergic reactions: rash, pruritus, or urticaria. - Stevens‑Johnson syndrome: rare severe skin reaction. - Hematologic abnormalities: rare cases of leukopenia or thrombocytopenia. - Hepatic dysfunction: occasional elevation of liver enzymes.

Before prescribing Molsidomine, clinicians should consider several safety aspects.

Avoid use in patients with severe hypotension: risk of further blood‑pressure decline. Monitor blood pressure regularly: especially after dose initiation or adjustment. Caution in patients with heart failure: may exacerbate low output. Do not combine with other nitric‑oxide donors without supervision: increased hypotensive risk. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Molsidomine can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - Concurrent nitrates (e.g., nitroglycerin): additive vasodilation leading to severe hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): risk of profound blood‑pressure fall. - Strong CYP3A4 inhibitors (if applicable): may increase linsidomine exposure.

Moderate Interactions (Monitor Closely): - Antihypertensive agents (beta‑blockers, ACE inhibitors): may enhance blood‑pressure lowering effect. - Diuretics: can potentiate orthostatic hypotension. - Alcohol: may increase dizziness and hypotensive episodes. - CYP3A4 inducers (e.g., rifampicin): could reduce efficacy. - Herbal vasodilators (e.g., ginkgo biloba): monitor for additive effects.